Jeffrey R. Stewart
Executive Vice President, Chief Commercial Officer at AbbVie
Thank you, Rob. I'm extremely pleased with the continued strong momentum across the therapeutic portfolio. I'll start with the quarterly results for immunology, which delivered total revenues of more than $7 billion, up 4.8% on an operational basis. Skyrizi global sales were $3.2 billion, up 51.5% on an operational basis, exceeding our expectations. We are seeing robust prescription growth across psoriatic disease with Skyrizi achieving in-play biologic share leadership in approximately now 30 key countries.
In the U.S., we continue to capture nearly one out of every two in-play psoriatic disease patients on biologic therapy, and we see substantial room for further total share growth. We believe that Skyrizi's best-in-class profile with nearly complete skin clearance, high durability of response, easy onboarding and quarterly dosing for maintenance therapy sets a very high bar relative to other therapies on-market or in development.
Skyrizi has also demonstrated a compelling clinical profile in IBD, including strong endoscopic data paired with convenient dosing. This differentiated profile as well as our compelling head-to-head sequence data versus Stelara is supporting very rapid uptake in Crohn's disease, where Skyrizi continues to gain market share globally, achieving in-play patient leadership across all lines of therapy in the U.S., Japan and Canada.
Skyrizi's U.S. in-play patient share is now approximately 32%, more than double the share of the second biologic treatment. And with Skyrizi's total prescription share of approximately 8%, we see significant opportunity for revenue inflection in Crohn's going forward. While we are still very early in our launch in the U.S. and Europe, we also anticipate robust uptake for Skyrizi in ulcerative colitis, the new indication. Initial prescription trends as well as feedback from gastroenterologists have been overwhelmingly positive.
Physicians are particularly impressed with the data that has been demonstrated for naive UC patients who have not been exposed yet to biologics, where Skyrizi achieved very high results for clinical remission and endoscopic response. We have now secured broad formulary access for Skyrizi in UC with sales in this indication expected to ramp meaningfully over the next several quarters. So, given the momentum we are seeing across all of these indications, we will be raising our full-year sales guidance once again for Skyrizi.
Turning now to Rinvoq, which is also demonstrating robust growth. Global sales were $1.6 billion, up 47.4% on an operational basis. We continue to see strong prescription growth across all seven of Rinvoq's approved indications. I'm especially pleased with our performance in IBD, where Rinvoq's uptake is exceeding our expectations. Rinvoq is now capturing double-digit in-play patient share in the U.S. for ulcerative colitis as well as Crohn's disease. Both indications are now available in more than 75 countries with reimbursement and share continuing to increase.
I also wanted to highlight our recent performance in atopic dermatitis, where Rinvoq is seeing an acceleration of in-play share following recent positive data from our second head-to-head study versus Dupixent. As an oral option that provides rapid skin clearance and itch relief, we believe Rinvoq's strong differentiated profile will continue to compete well in this highly underpenetrated AD market. As a result of this continued strong performance, we will also be increasing the full-year sales guidance once again for Rinvoq.
Looking forward, we see substantial momentum for both Skyrizi and Rinvoq, including continued share gains across existing indications on top of the typical underlying market growth across rheum, derm and gastro. Additionally, we are making excellent progress with several new indications for Rinvoq across sizable markets that will have the potential to provide another significant revenue inflection in the second half of this decade and into the 2030s.
From a competitive perspective, a key element of Skyrizi and Rinvoq's success has been their strong differentiation with compelling head-to-head data against several novel therapies. This includes Skyrizi superiority versus Humira, Cosentyx, Otezla and Stelara in psoriasis as well as Stelara in Crohn's disease and Rinvoq superiority versus Humira and Arencia in rheumatoid arthritis, as well as Dupixent in atopic dermatitis.
To further support our differentiation, we have another head-to-head study ongoing for Skyrizi versus Sotyktu in psoriasis with plans also underway now for a study comparing Skyrizi versus Entyvio in ulcerative colitis. So, given all of these factors, we feel very confident about the long-term growth prospects for both Skyrizi and Rinvoq.
Turning now to Humira, which delivered global sales of $2.2 billion, down 36.5% on an operational basis due to biosimilar competition. While Humira's share erosion to biosimilars in the U.S. is largely in-line with our expectations, we are now seeing more Humira molecule volume moving to other novel mechanisms than previously anticipated. So, while this has an unfavorable impact to Humira sales, we are seeing a benefit to Skyrizi and Rinvoq, which is a very favorable dynamic for immunology portfolio now and certainly over the long-term.
Moving now to oncology where total revenues were approximately $1.7 billion. Imbruvica global revenues were $828 million, down 8.8%, reflecting continued competitive dynamics in CLL, partially offset by higher persistency rates for existing patients. Venclexta is performing extremely well. Global sales were $677 million, up 18.2% on an operational basis. This reflects strong momentum in CLL, especially in Europe, where recent guideline changes recommend combination use of Venclexta plus BTK inhibitors as a preferred fixed duration treatment versus continuous BTK treatment alone.
Growth is also supported by our very strong share position in frontline AML, where Venclexta is the leading treatment for patients who are ineligible for intensive induction chemotherapy. We are also seeing nice sequential revenue growth from Elahere and Epkinly, which are both demonstrating strong launch trajectories.
Turning now to neuroscience, where total revenues were more than $2.3 billion, up 16% on an operational basis. Vraylar is demonstrating robust performance. Sales were $875 million, up 16.6% on an operational basis, reflecting continued new prescription growth in both bipolar disorder and adjunctive MDD. Within migraine, our leading oral CGRP therapies contribute $445 million in combined revenue this quarter, reflecting growth of approximately 22% as we continue to see increasing prescription demand for both Ubrelvy and Qulipta. Global Botox therapeutic sales were $848 million, reflecting strong performance in chronic migraine as well as the other approved indications.
Finally, we are very excited for the recent U.S. approval of Vyalev, a transformative therapy for patients with advanced Parkinson's disease who are uncontrolled on oral therapy alone. As a less invasive, non-surgical delivery system that can provide meaningful improvements in on-time and off-time, we believe Vyalev has the potential to significantly expand use beyond current device-aided therapies. Sales in the U.S. for Vyalev are expected to ramp gradually over the next several quarters as we work to establish the appropriate Medicare coverage and benefit determination.
At the same time, we are very encouraged by the interest and uptake internationally, where we have approval now in 35 countries with several thousand patients already on treatment. Longer term, we anticipate peak sales of Vyalev to exceed $1 billion. So, overall, I'm very pleased with the continued commercial execution and performance across the therapeutic portfolio.
And with that, I'll turn the call over to Carrie for additional comments on aesthetics. Carrie?